Aimovig halved migraine days-in-30% of-trial-patients-

18 April 2018

Positive new data on what is likely the first drug in a new class designed to target calcitonin gene-related peptide (CGRP), which plays a key role in migraine activation, has been released.

Switzerland’s Novartis (NOVN: VX) and US biotech Amgen (Nasdaq: AMGN) on Thursday announced full results from the Phase IIIb LIBERTY trial of Aimovig (erenumab, AMG 334) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or intolerable side effects.

Evercore ISI analyst Umer Raffat has estimated that the market for anti-CGRP drugs could reach $8 billion to $10 billion. Mr Raffat estimated that anti-CGRP drugs will likely be priced at about $8,500 a year, in line with the cost of PCSK9 inhibitors.

Others in the field

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK